SCHEMBL9933162

SCHEMBL9933162

Cn1cc(-c2ccnc3c2CCNCC3)c(-c2ccc(F)cc2)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 9/20 0.61
MAPK14 Q16539 6/20 0.61
CSNK1E P49674 6/20 0.61
MAPK11 Q15759 5/20 0.61
MAPK13 O15264 3/20 0.61
MAPK12 P53778 3/20 0.61
KCNH2 Q12809 3/20 0.61
MAP4K4 O95819 2/20 0.56
MAPK9 P45984 2/20 0.56
CSNK1A1 P48729 2/20 0.56
NUAK1 O60285 1/20 0.56
ROCK2 O75116 1/20 0.56
LCK P06239 1/20 0.56
MAPK8 P45983 1/20 0.56
GSK3B P49841 1/20 0.56
MAP2K1 Q02750 1/20 0.56
MINK1 Q8N4C8 1/20 0.56
AURKB Q96GD4 1/20 0.56
EGFR P00533 1/20 0.48
FRK P42685 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9932158 0.92 CSNK1D (0.69) CSNK1DMAPK14CSNK1EMAPK11MAPK13
SCHEMBL9932617 0.92 CSNK1D (0.66) CSNK1DMAPK14CSNK1EMAPK11MAPK13
SCHEMBL9961409 0.88 CSNK1D (0.47) CSNK1DMAPK14CSNK1EMAPK11MAPK13
SCHEMBL9933429 0.87 CSNK1D (0.60) CSNK1DMAPK14CSNK1EMAPK11MAPK13
SCHEMBL9932276 0.84 CSNK1D (0.67) CSNK1DMAPK14CSNK1EMAPK11MAPK13
SCHEMBL9932956 0.80 CSNK1D (0.67) CSNK1DMAPK14CSNK1EMAPK11MAPK13
SCHEMBL9933228 0.80 CSNK1D (0.55) CSNK1DMAPK14CSNK1EMAPK11MAPK13
SCHEMBL9933413 0.80 CSNK1D (0.55) CSNK1DMAPK14CSNK1EMAPK11MAPK13
SCHEMBL25324837 0.78 CSNK1D (0.56) CSNK1DMAPK14CSNK1EMAPK11MAPK13
SCHEMBL30509346 0.78 CSNK1D (0.56) CSNK1DMAPK14CSNK1EMAPK11MAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3181133-A1 NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS Pfizer Inc (US) 2017-06-21 EP disclosed
EP-2654750-A1 NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS Pfizer Inc (US) 2013-10-30 EP disclosed
US-8536164-B2 Fused pyridine compounds as casein kinase inhibitors PFIZER INC. (US) 2013-09-17 US disclosed
WO-2012085721-A1 NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS PFIZER INC. (US) 2012-06-28 WO disclosed
US-20120157440-A1 NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS PFIZER INC 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157440-A1 NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS CSNK1A1, CSNK1A1L, CSNK1E CSNK1D 10/4885MAPK14 270/4885CSNK1E 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.